MedTrace Logo

Assessment of Prognosis Using Peripheral Blood Circulating Tumor DNA in Patients With Cervical Cancer

NCT05602831 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 108

Last updated 2022-11-02

No results posted yet for this study

Summary

This observational study is conducted to assess the value of using peripheral blood ctDNA to detect dynamic changes in HPV and genetic variants in predicting the prognosis of patients with locally advanced cervical cancer, as compared with traditional imaging and tumor markers.

Conditions

  • Locally Advanced Cervical Cancer

Interventions

OTHER

detect HPV and genetic variants

Serum tumor markers and ctDNA HPV and genetic variants will be detected in peripheral blood samples. HPV and genetic variants will be also detected in baseline surgical tissues.

OTHER

detect HPV and genetic variants

Serum tumor markers and ctDNA HPV and genetic variants will be detected in peripheral blood samples. HPV and genetic variants will be also detected in baseline puncture tissues.

Sponsors & Collaborators

  • Amoy Diagnostics

    collaborator INDUSTRY

  • Fudan University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-10
Primary Completion
2024-07-31
Completion
2024-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05602831 on ClinicalTrials.gov